EXPRESSION OF HYPOXIA-INDUCING FACTOR-1α AND ENDOGLIN IN INTIMAL HYPERPLASIA OF THE MIDDLE CEREBRAL ARTERY OF PATIENTS WITH MOYAMOYA DISEASE

Takagi, Yasushi; Kikuta, Ken-ichiro; Nozaki, Kazuhiko; Fujimoto, Motoaki; Hayashi, Junzo; Imamura, Hirotoshi; Hashimoto, Nobuo

doi:10.1227/01.neu.0000249275.87310.ff

Cited by 65 publications

(46 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased expression of angiogenic factors such as hypoxia-inducing factor-1α, vascular endothelial growth factor (VEGF), basic fibroblast growth factor, granulocyte colony stimulating factor (G-CSF), transforming growth factor-β1 (TGFβ1) and hepatocyte growth factor was observed both in CSF and serum of MMD patients [33][34][35][36] . Significant expression of VEGF was found also around the affected vasculature and in glial cells [36] .…”

Section: Angiogenesis Extracellular Matrix Remodelingmentioning

confidence: 99%

Research Progresses in Understanding the Pathophysiology of Moyamoya Disease

et al. 2016

View full text Add to dashboard Cite

Background: The pathogenesis of moyamoya disease (MMD) is still unknown. The detection of inflammatory molecules such as cytokines, chemokines and growth factors in MMD patients' biological fluids supports the hypothesis that an abnormal angiogenesis is implicated in MMD pathogenesis. However, it is unclear whether these anomalies are the consequences of the disease or rather causal factors as well as these mechanisms remain insufficient to explain the pathophysiology of MMD. The presence of a family history in about 9-15% of Asian patients, the highly variable incidence rate between different ethnic and sex groups and the age of onset support the role of genetic factors in MMD pathogenesis. However, although some genetic loci have been associated with MMD, few of them have been replicated in independent series. Recently, RNF213 gene was shown to be strongly associated with MMD occurrence with a founder effect in East Asian patients. However, the mechanisms leading from RNF213 mutations to MMD clinical features are still unknown. Summary: The research on pathogenic mechanism of MMD is in its infancy. MMD is probably a complex and heterogeneous disorder, including different phenotypes and genotypes, in which more than a single factor is implicated. Key Message: Since the diagnosis of MMD is rapidly increasing worldwide, the development of more efficient stratifying risk systems, including both clinical but also biological drivers became imperative to improve our ability of predict prognosis and to develop mechanism-tailored interventions.

show abstract

Section: Angiogenesis Extracellular Matrix Remodelingmentioning

confidence: 99%

Research Progresses in Understanding the Pathophysiology of Moyamoya Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…14,25,35,50,78,81 This native revascularization strategy is orchestrated by the expression of various growth factors involved in angiogenic signaling cascades, including HIF-1, VEGF, bFGF, transforming growth factor-β 1 , hepatocyte growth factor, and MMPs. 24,43,50,70,81 Taken together these studies indicate the existence of a proangiogenic intracranial milieu in patients with moyamoya disease. Future investigations are needed that focus on highthroughput proteome-wide approaches that go beyond individual molecules to provide a better insight into global pathways and interactions at play in moyamoya disease and that correlate expression levels to extent of disease on neuroimaging (for example, correlation of angiogenic factors in CSF, serum, and urine to extent of collateralization seen on cerebral angiography and measurements of cerebral blood flow and blood volume on perfusion MR imaging/SPECT/PET).…”

Section: Pathophysiology: Histology To Proteomicsmentioning

confidence: 61%

Pathophysiology and genetic factors in moyamoya disease

Achrol

Guzman²,

Lee³

et al. 2009

FOC

113

View full text Add to dashboard Cite

Moyamoya disease is an uncommon cerebrovascular condition characterized by progressive stenosis of the bilateral internal carotid arteries with compensatory formation of an abnormal network of perforating blood vessels providing collateral circulation. The etiology and pathogenesis of moyamoya disease remain unclear. Evidence from histological studies, proteomics, and endothelial progenitor cell analyses suggests new theories underlying the cause of vascular anomalies, including moyamoya disease. Familial moyamoya disease has been noted in as many as 15% of patients, indicating an autosomal dominant inheritance pattern with incomplete penetrance. Genetic analyses in familial moyamoya disease and genome-wide association studies represent promising strategies for elucidating the pathophysiology of this condition. In this review, the authors discuss recent studies that have investigated possible mechanisms underlying the etiology of moyamoya disease, including stem cell involvement and genetic factors. They also discuss future research directions that promise not only to offer new insights into the origin of moyamoya disease but to enhance our understanding of new vessel formation in the CNS as it relates to stroke, vascular anomalies, and tumor growth.

show abstract

“…Por otra parte, diversos reportes de pacientes con EMM han mostrado niveles elevados en suero y/o líquido cefalorraquídeo de factores de crecimiento como el factor de crecimiento de fibroblastos, el factor de crecimiento transformante beta (TGF-β1), el factor de crecimiento de hepatocitos, etc. ; y otros péptidos como lasmetaloproteinasas de la matriz (MMP-9), las moléculas de adhesión intracelular y el factor inducible por hipoxia 1α (12,13), los cuales contribuirían con el desarrollo de las alteraciones histológicas propias de la enfermedad (14).En nuestro paciente no se realizó ni el análisis genético ni la detección de los biomarcadores debido a que en su mayoría no están disponibles en el país.…”

Section: Rev Neuropsiquiatr 78 (3) 2015unclassified

Enfermedad de Moyamoya: reporte de un caso.

Ramírez-Quiñones¹,

Barrientos-Imán²,

Rosa³

et al. 2015

Rev Neuropsiquiatr

View full text Add to dashboard Cite

La enfermedad de Moyamoya es una patología caracterizada por la estenosis progresiva de la arteria carótida interna y sus ramas principales. Es de etiología desconocida, tiene como forma de presentación a la enfermedad cerebrovascular isquémica o hemorrágica, siendo la primera más frecuente, y afecta en mayor proporción a niños y adultos jóvenes constituyendo un reto diagnóstico. Su presencia se confirma mediante la angiografía por sustracción digital (ASD) y el manejo es médico y/o quirúrgico, siendo el último el que se asocia a un mejor pronóstico. Comunicamos el caso de un paciente peruano de ascendencia japonesa, sin factores de riesgo, con una hemorragia intracraneal cuyo diagnóstico final fue enfermedad de Moyamoya.

show abstract

EXPRESSION OF HYPOXIA-INDUCING FACTOR-1α AND ENDOGLIN IN INTIMAL HYPERPLASIA OF THE MIDDLE CEREBRAL ARTERY OF PATIENTS WITH MOYAMOYA DISEASE

Abstract: Our results indicate that the MCA specimens from MMD patients had thicker intimal walls than the specimens from control patients. In addition, hypoxia-inducing factor-1alpha and endoglin were overexpressed in the intima of the MCA of MMD patients.

Cited by 65 publications

References 32 publications

Research Progresses in Understanding the Pathophysiology of Moyamoya Disease

Research Progresses in Understanding the Pathophysiology of Moyamoya Disease

Pathophysiology and genetic factors in moyamoya disease

Enfermedad de Moyamoya: reporte de un caso.

Contact Info

Product

Resources

About